Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.